Syncona Limited Autolus announces launch of proposed offering (5821V)
April 09 2019 - 2:01AM
UK Regulatory
TIDMSYNC
RNS Number : 5821V
Syncona Limited
09 April 2019
Syncona Limited
Autolus announces launch of proposed public offering in the
United States
LONDON, 9 April 2019
Syncona Ltd, a leading healthcare company focused on founding,
building and funding global leaders in life science, today notes
that its portfolio company, Autolus Therapeutics plc has filed a
registration statement on Form F-1 with the U.S. Securities and
Exchange Commission (the "SEC") relating to a proposed underwritten
public offering in the United States of its American Depositary
Shares ("ADSs"), each ADS representing one ordinary share.
The proposed maximum aggregate offering amount specified in the
filing is 4,000,000 ADSs, which does not include the underwriters'
option to purchase 600,000 additional ADSs. The final price per ADS
in the offering will be determined following a bookbuilding
process.
The registration statement can be accessed through the SEC's
EDGAR database.
This announcement does not constitute an offer to sell or the
solicitation of an offer to buy securities, and shall not
constitute an offer, solicitation or sale in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of that
jurisdiction.
The securities referred to in this announcement are to be
offered only by means of a prospectus. When available, copies of
the preliminary prospectus can be obtained from Goldman Sachs &
Co. LLC, Attention: Prospectus Department, 200 West Street, New
York, NY 10282, or by telephone at +1 866 471 2526 or by email at
prospectus-ny@ny.email.gs.com; or Jefferies LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New
York, NY 10022, or by telephone at +1 877 821 7388 or by email at
Prospectus_Department@Jefferies.com. For the avoidance of doubt,
such prospectus will not constitute a "prospectus" for the purposes
of Directive 2003/71/EC (and amendments thereto, including
Directive 2010/73/EU, to the extent implemented in each relevant EU
member state) and will not have been reviewed by any competent
authority in any EU member state.
[ENDS]
Enquiries
Syncona Ltd
Siobhan Weaver / Annabel Clay
Tel: +44 (0)20 3981 7940
This announcement includes information that is inside
information as defined in Article 7 of the Market Abuse Regulation
(EU) No.596/2014. The person responsible for arranging for the
release of this announcement on behalf of Syncona Ltd is Andrew
Cossar, General Counsel, SIML.
Forward-looking statements - this announcement contains certain
forward-looking statements with respect to the portfolio of
investments of Syncona Ltd. These statements and forecasts involve
risk and uncertainty because they relate to events and depend upon
circumstances that may or may not occur in the future. There are a
number of factors that could cause actual results or developments
to differ materially from those expressed or implied by these
forward-looking statements and forecasts. Nothing in this
announcement should be construed as a profit forecast.
About Syncona
Syncona is a leading FTSE250 healthcare company focused on
founding, funding and building global leaders in life science. Our
vision is to deliver transformational treatments to patients in
truly innovative areas of healthcare while generating superior
returns for shareholders.
We seek to partner with the best, brightest and most ambitious
minds in science to build globally competitive businesses.
We take a long-term view, underpinned by a deep pool of capital,
and are established leaders in gene and cell therapy. We focus on
delivering dramatic efficacy for patients in areas of high unmet
need.
About Autolus
Autolus is a biopharmaceutical company developing
next-generation programmed T cell therapies for the treatment of
cancer.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
PFUUKOVRKRASRRR
(END) Dow Jones Newswires
April 09, 2019 02:01 ET (06:01 GMT)
Syncona (LSE:SYNC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Syncona (LSE:SYNC)
Historical Stock Chart
From Apr 2023 to Apr 2024